Notices. Notice

5,414 words·~25 min read·/register/2006/05/02/06-4126

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4140-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, Public Health Service, HHS. ACTION: Notice. SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development.

Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone:

(301)496-7057; fax:

(301)402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Predictive Test for Age-Related Macular Degeneration in Asymptomatic Individuals *Description of Technology:* Age-related macular degeneration

(ARMD)is the leading cause of severe, irreversible vision loss for those over the age of fifty in the United States and in other developed countries. Thirteen million Americans over the age of forty have ARMD. ARMD is caused by the deterioration of the central area of the retina, or macula, resulting in a loss of central vision. This disease is believed to be a multigenic disorder, and is triggered by environmental factors such as smoking, age or diet in genetically susceptible individuals. The present invention describes a highly predictive genetic test for universal practical clinical use to identify individuals at increased risk for ARMD. It comprises a rapid, accurate and affordable genetic screen, utilizing DNA microarray technology on a single chip. Sixteen genes are screened for 90 mutations/polymorphisms associated with ARMD, with a high predictive power (up to 92.7%) to identify asymptomatic carriers at risk. Accurate prediction of genetic susceptibility to this disorder will allow interventions to protect at-risk individuals. *Application(s):* Diagnostic kit to identify asymptomatic individuals at risk for age-related macular degeneration; make possible the identification of genetic factors in an affected individual, aiding in the development of a tailored therapeutic plan; provide genetic epidemiologic data to elucidate the role of genetic factors in the progression of the disease. *Market:* Individuals at risk for age-related macular degeneration. There are an estimated 15 million cases of age-related macular degeneration in the United States, and 50 million cases worldwide. *Development Status:* This technology requires analytic validation before commercialization. *Inventors:* Cigdem F. Dogulu, Owen M. Rennert, and Wai-Yee Chan (NICHD) *Patent Status:* U.S. Provisional Application No. 60/733,042 filed 02 Nov 2005 (HHS Reference No. E-023-2006/0-US-01) *Licensing Status:* Available for non-exclusive or exclusive licensing. *Licensing Contact:* Fatima Sayyid, M.H.P.M.; 301/435-4521; *sayyidf@mail.nih.gov* *Collaborative Research Opportunity:* The NICHD Laboratory of Clinical Genomics is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Method Evolved for Recognition and Testing of Age-Related Macular Degeneration (MERT-ARMD). Please contact Kenneth J. Rose, Esq, PhD., at

(301)496-0477 or *rosek@mail.nih.gov* for more information. Method for Promoting Stem Cell Survival *Description of Technology:* Regenerative medicine holds the potential to revolutionize the treatment of a host of diseases, such as neurodegenerative disorders, stroke, and many others. Stem cell technologies are a central focus of regenerative medicine research and treatment of cancer. An essential component of this research is the ability to control stem cell survival. This technology describes a method to promote stem cell survival and proliferation by manipulating the phosphorylation state a key protein in these processes. This method has been shown to enhance survival and proliferation in stem cell cultures in vitro, and also in neuronal precursor cells in vivo. *Application(s):* Clinical treatment for stroke and other neurodegenerative diseases by administration of agents that promote stem cell survival and proliferation; increased generation of stem cells in vitro; diagnostic assay for cancer to determine the phosphorylation state of the protein in tumors; screening assays for agents that promote proliferation of stem cells or inhibit proliferation of cancer cells. *Market:* Treatment for neurodegenerative disorders such as Parkinson's disease or stroke; prognostic marker to help determine response of individuals with cancer; commercial suppliers or large-scale users of stem cells. *Development Status:* Early stage. *Inventors:* Andreas Androutsellis-Theotokis and Ronald D.G. McKay (NINDS). *Patent Status:* U.S. Provisional Application No. 60/715,935 filed 08 Sep 2005 (HHS Reference No. E-239-2005/0-US-01). *Licensing Status:* Available for non-exclusive or exclusive licensing. *Licensing Contact:* Fatima Sayyid, M.H.P.M.;

(301)435-4521; *sayyidf@mail.nih.gov.* *Collaborative Research Opportunity:* The National Institute of Neurological Disorders and Stroke is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize agents that inhibit or induce phosphorylation of a protein that is a key regulator of proliferation and survival of stem cells and precursor cells. Please contact Martha Lubet at

(301)435-3120 or *lubetm@mail.nih.gov.* Dated: April 24, 2006. Steven M. Ferguson, Director, Division of Technology Development and Transfer Office of Technology Transfer, National Institutes of Health. [FR Doc. E6-6547 Filed 5-1-06; 8:45 am] BILLING CODE 4167-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, Public Health Service, HHS. ACTION: Notice. SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone:

(301)496-7057; fax:

(301)402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Monoclonal Antibody for Lyme Disease Diagnostic and Research Alan G. Barbour (NIAID) HHS Reference No. E-075-2006/0—Research Materials Licensing Contact: Susan Ano; 301/435-5515; *anos@mail.nih.gov* The hybridoma producing a monoclonal antibody against the major flagellin protein

(FlaB)is available for licensing. This antibody can be used in diagnostic and research applications related to Lyme disease or other Borrelia-caused conditions. More information about this antibody can be found in Barbour *et al.* , Infection and Immunity, May 1986, volume 52(5), pages 549-554. Broad Spectrum Antiviral Compounds Gary J. Nabel and Jae Ouk Kim (NIAID) U.S. Provisional Application No. 60/775,666 filed 21 Feb 2006 (HHS Reference No. E-013-2006/0-US-01) Licensing Contact: Susan Ano; 301/435-5515; *anos@mail.nih.gov* This technology relates to broad spectrum antiviral compounds for treatment of infection caused by enveloped viruses. The compounds are fusions molecules of a phospholipase and a viral binding polypeptide. The subject technology requires the phospholipase component of the antiviral compound to have enzymatic activity, whereas previous studies demonstrating antiviral activity of some phospholipases did not require enzymatic activity. The compounds described by the current technology are not necessarily virus or viral strain specific, unlike many currently available antiviral compounds. The antiviral activity of the compounds has been demonstrated in vitro with representative viruses pseudotyped with envelope proteins from Ebola, HIV, Marburg, and VSV. Additionally, the antiviral activity was demonstrated with wild type HIV. The potential broad application of these compounds could address a significant health need for effective antivirals. The Vaccine Research Center at the National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize treatments or vaccines against infections caused by enveloped viruses. Please contact Anna Z. Amar at 301/451-3525 and/or *aamar@niaid.nih.gov* for more information. Increased Cytokine Expression Barbara Felber and George Pavlakis

(NCI)U.S. Provisional Application No. 60/758,819 filed 13 Jan 2006 (HHS Reference No. E-254-2005/0-US-01) U.S. Provisional Application No. 60/758,680 filed 13 Jan 2006 (HHS Reference No. E-267-2005/0-US-01) Licensing Contact: Susan Ano; 301/435-5515; *anos@mail.nih.gov* The current technologies describe optimization of the genes encoding interleukins 12 (IL-12) and 15 (IL-15), resulting in higher levels of protein expression. Cytokines play an important role in both innate and adaptive immune responses. Their utility as immunotherapeutics against infectious disease and cancer as well as vaccine adjuvants has been previously demonstrated. However, cytokine expression from native sequences can be sub-optimal for several reasons, including potential splice sites within RNA and low stability coding sequences. The current technologies offer a means to increase expression of these important molecules. In vitro studies show a 5- to 10-fold mean increase in cytokine protein production. In some instances, further increased expression was achieved by use of a heterologous signal peptide. The subject technologies have application to DNA vaccination and treatment of diseases such as HIV, hepatitis B or C, cancer, and influenza. Some fields of use may not be available for licensing. Dated: April 24, 2006. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E6-6548 Filed 5-1-06; 8:45 am] BILLING CODE 4167-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, Public Health Service, HHS. ACTION: Notice. SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Tetracyclines and Derivatives as Inhibitors of Human Tyrosyl-DNA-phosphodiesterase

(Tdp1)*Description of Technology:* The invention describes tetracycline compounds and their derivatives as having anticancer activity, as well as methods of treating cancer. Tetracyclines are commonly used as antibiotics, however testing of these compounds in a high throughput screening system for Tdp1 inhibitors revealed them to be potent Tdp1 inhibitors. Tdp1 is known to be important for mutation avoidance under normal growth conditions. Tetracyclines derivatives are expected to increase the selectivity of chemotherapeutic agents ( *e.g.* camptothecin), for tumors, thereby increasing the antitumor activity while reducing their side effects. *Inventors:* Yves Pommier, Christophe Marchand, Laurent Thibaut (NCI). *Patent Status:* U.S. Provisional Application filed March 27, 2006 (HHS Reference No. E-097-2006/0-US-01). *Licensing Status:* Available for non-exclusive or exclusive licensing. *Licensing Contact:* Richard Rodriguez; 301/435-4013; *rodrigr@mail.nih.gov.* *Collaborative Research Opportunity:* The Laboratory of Molecular Pharmacology at the National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize tetracycline derivatives, particularly optimizing them for therapeutic use. Please contact Lisa Finkelstein at 301-451-7458 for more information. Insect Cell Production of Recombinant Adeno-Associated Virus That Produce Cytotoxic Gene Products and Applications for Solid Tumor Therapy *Description of Technology:* Cancer is the second leading cause of death in United States and it is estimated that there will be approximately 600,000 deaths caused by cancer in 2006. Due to the high incidence of death from cancer despite the use of current therapies, there is a strong need for targeted therapeutic approaches such as gene therapy. This technology describes a new method for targeting solid tumors using gene therapy. More specifically, mammalian HEC-1 has a critical role in chromosome segregation and thus cell division. This technology involves targeted depletion of HEC-1 using shRNA against the HEC-1 mRNA inhibiting cancer cell growth in cell culture models ( *in vitro* ) as well as regressed tumor size in mouse model ( *in vivo* ). Additionally, this is the sole technology using an insect cell based recombinant adeno-associated virus

(rAAV)gene transfer vehicle with high titer containing the shRNA of interest thus enabling high dosing during therapeutic intervention if necessary. This technology platform has the potential to treat a broad spectrum of cancers and related diseases. *Applications:* A new anti-cancer adjuvant therapy for non-resectable tumors targeting HEC-1 protein; a new method involving insect cell based production of recombinant adeno-associated virus

(rAAV)gene transfer vehicle. *Market:* 600,000 deaths from cancer related diseases estimated in 2006. The technology platform involving new cancer therapy and gene therapy technology has a potential market of more than 50 billion dollars. *Development Status:* The technology is currently in pre-clinical stage of development. *Inventors:* Robert M. Kotin and Lina Li (NHLBI). *Publications:* 1. EN Gurzov *et al.* , “RNA Interference against Hec 1 inhibits tumor growth in vivo,” *Gene Ther.* 2006 Jan; 13 (1):1-7. 2. JG DeLuca *et al.* , “Hec1 and nuf2 are core components of the kinetochore outer plate essential for organizing microtubule attachment sites,” *Mol Biol Cell.* 2005 Feb; 16 (2):519-531. 3. S Martin-Lluesma *et al.* , “Role of Hec1 in spindle checkpoint signaling and kinetochore recruitment of Mad1/Mad2,” *Science* 2002 Sep 27; 297 (5590):2267-2270. 4. T Hori *et al.* , “Dynamic behavior of Nuf2-Hec1 complex that localizes to the centrosome and centromere and is essential for mitotic progression in vertebrate cells,” *J Cell Sci.* 2003 Aug 15; 116 (Pt 16):3347-3362. 5. Y Chen *et al.* , “Phosphorylation of the mitotic regulator protein Hec1 by Nek2 kinase is essential for faithful chromosome segregation,” *J Biol Chem.* 2002 Dec 20; 277 (51):49408-49416. *Patent Status:* U.S. Provisional Application No. 60/782,277 filed 15 Mar 2006 (HHS Reference No. E-200-2005/0-US-01). *Licensing Status:* Available for non-exclusive or exclusive licensing. *Licensing Contact:* Jesse S. Kindra, J.D.; 301/435-5559; *kindraj@mail.nih.gov.* *Collaborative Research Opportunity:* The National Heart, Lung, and Blood Institute, Laboratory of Biochemical Genetics, is seeking statements of capability or interest from parties interested in collaborative research to further develop therapeutics using rAAV-shRNA to induce selective cytotoxicity in primary and metastatic solid tumors. Partners are sought for conducting translational research from preclinical trials to clinical trials. Please contact Dr. Vincent Kolesnitchenko, Office of Technology Transfer and Development, NHLBI at 301-594-4115 or by e-mail ( *vk5q@nih.gov* ) for more information. Identification of a Novel Folliculin Interacting Protein, FNIP-1 *Description of Technology:* Renal cell carcinoma is an important health problem in the United States, affecting 32,000 individuals each year and resulting in 12,000 deaths annually. Several familial cancer disorders with a renal epithelial tumor phenotype have been well characterized and the causative genes have been identified including the Birt-Hogg-Dube

(BHD)gene. The BHD gene encodes a protein called folliculin. Mutations in BHD lead to the development of Birt-Hogg Dube syndrome, a dermatologic disorder associated with an increased risk for developing renal cancer, spontaneous pneumothorax and lung cysts. This invention describes the cloning and characterization of the first folliculin interacting protein FNIP-1 and purified antibodies that selectively bind to an epitope of FNIP-1. FNIP-1 interacts with subunits of AMP-dependent protein kinase (AMPK). The FNIP-1/AMPK interaction places FNIP-1 and folliculin as potential interactors in cellular pathways essential for regulating cell growth and cell size. FNIP-1 may play an important role in folliculin's function. Identification of the FNIP-1 cDNA sequence will enable evaluation of sporadic renal tumors, enable the development of cancer diagnostics and aid in the treatment of BHD skin lesions. *Inventors:* Laura S. Schmidt *et al.* (NCI). *Patent Status:* U.S. Provisional Application No. 60/689,749 filed June 9, 2005 (HHS Reference No. E-139-2005/0-US-01). *Licensing Status:* Available for non-exclusive or exclusive licensing. *Licensing Contact:* John Stansberry, Ph.D.; 301/435-5236; *stansbej@mail.nih.gov.* *Collaborative Research Opportunity:* The National Cancer Institute, Center for Cancer Research, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize folliculin interacting protein FNIP-1 and purified antibodies. Please contact Kathy Higinbotham at 301-846-5465 or *higinbok@mail.nih.gov* for more information. Bone Morphogenetic Variants, Compositions and Methods of Treatment *Description of Technology:* The invention identifies proteins belonging to TGF-Beta superfamily that promote repair of menisci, cruciate and collateral ligaments of the knee, and rotator cuff tendons. The application claims nucleic acids encoding human Cartilage-Derived Morphogenetic Protein-1 (hCDMP-1) variant polypeptides. Morphogenetic proteins are able to induce the proliferation and differentiation of progenitor cells into functional bone, cartilage, tendon, or ligament tissue. *Inventors:* Malcolm C. Moos *et al.* (FDA). *Patent Status:* U.S. Provisional Application No. 60/689,346 filed June 9, 2005 (HHS Reference No. E-196-2004/0-US-01). *Licensing Status:* Available for non-exclusive or exclusive licensing. *Licensing Contact:* Thomas P. Clouse, J.D.; 301/435-4076; *clouset@mail.nih.gov.* Dated: April 25, 2006. David R. Sadowski, Acting Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E6-6549 Filed 5-1-06; 8:45 am] BILLING CODE 4140-01-P DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT [Docket No. FR-5052-N-02] Notice of Proposed Information Collection: Comment Request; Applicant/Recipient Disclosure/Update Report—HUD 2880 AGENCY: Office of the General Counsel, HUD. ACTION: Notice. SUMMARY: The proposed information collection requirement described below will be submitted to the Office of Management and Budget

(OMB)for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal. DATES: *Comments Due Date:* July 3, 2006. ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Brenda M. Johnson, Reports Liaison Officer, Department of Housing and Urban Development, 451 Seventh Street, SW., Room 10276, Washington, DC 20410-0500. FOR FURTHER INFORMATION CONTACT: Timothy Wray, Senior Attorney-Advisor, Ethics Law Division, Office of General Counsel, Department of Housing and Urban Development, 451 Seventh Street, SW., Room 2130, Washington, DC 20410-0500, telephone

(202)708-3815 (this is not a toll-free number). This form can be viewed or accessed at *http://www.hudclips.org/sub_nonhud/cgi/pdfforms/2880.pdf.* SUPPLEMENTARY INFORMATION: The Department is submitting the proposed information collection to OMB for review, as required by the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35, as amended). This notice is soliciting comments from members of the public and affecting agencies concerning the proposed collection of information to:

(1)Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2)Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information;

(3)Enhance the quality, utility, and clarity of the information to be collected; and

(4)Minimize the burden of the collection of information on those who are to respond; including through the use of appropriate automated collection techniques or other forms of information technology, *e.g.* , permitting electronic submission of responses. This Notice also lists the following information: *Title of Proposal:* Applicant/Recipient Disclosure/Update Report. *OMB Control Number, if applicable:* 2510-0011. *Description of the need for the information and proposed use:* Section 102 of the Department of Housing and Urban Development Reform Act of 1989 (HUD Reform Act) requires the Department to ensure greater accountability and integrity in the provision of assistance administered by the Department. One feature of the statute requires certain disclosures by applicants seeking assistance from HUD, assistance from states and units of local government, and other assistance to be used with respect to the activities to be carried out with the assistance. The disclosure includes the financial interests of persons in the activities, and the sources of funds to be made available for the activities, and the proposed uses of the funds. Each applicant that submits an application for assistance, within the jurisdiction of the HUD, to a state or to a unit of general local government for a specific project or activity must disclose this information whenever the dollar threshold is met. This information must be kept updated during the application review process and while the assistance is being provided. *Agency form numbers, if applicable:* HUD 2880. *Members of affected public:* Applicants for HUD competitively funded assistance. *Estimation of the total numbers of hours needed to prepare the information collection including number of respondents, frequency of response, and hours of response:* The form, HUD 2880, must be submitted as part of an applicant's application for competitively funded assistance. Number of respondents Burden hours Frequency of response Total burden hours 16,900 2.0 1.2 40,560 *Status of the proposed information collection:* Extension of a currently approved collection. Authority: The Paperwork Reduction Act of 1995, 44 U.S.C. Chapter 35, as amended. Dated: April 25, 2006. Camille E. Acevedo, Associate General Counsel for Legislation and Regulations. [FR Doc. E6-6544 Filed 5-1-06; 8:45 am] BILLING CODE 4210-67-P DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT [Docket No. FR-5052-N-04] Notice of Proposed Information Collection: Comment Request; Legal Instructions Concerning Applications for Full Insurance Benefits—Assignment of Multifamily Mortgages to the Secretary AGENCY: Office of the General Counsel, HUD. ACTION: Notice. SUMMARY: The proposed information collection requirement described below will be submitted to the Office of Management and Budget

(OMB)for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal. DATES: *Comments Due Date:* July 3, 2006. ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Brenda M. Johnson, Reports Liaison Officer, Department of Housing and Urban Development, 451 Seventh Street, SW., Room 10276, Washington, DC 20410-0500. FOR FURTHER INFORMATION CONTACT: Millicent Potts, Assistant General Counsel for Multifamily Mortgage Division, Office of General Counsel, Department of Housing and Urban Development, 451 Seventh Street, SW., Room 9230, Washington, DC 20410-0500, telephone

(202)708-4090 (this is not a toll-free number) for a copy of the instructions. SUPPLEMENTARY INFORMATION: The Department is submitting the proposed information collection to OMB for review, as required by the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35, as amended). This notice is soliciting comments from members of the public and affecting agencies concerning the proposed collection of information to:

(1)Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2)Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information;

(3)Enhance the quality, utility, and clarity of the information to be collected; and

(4)Minimize the burden of the collection of information on those who are to respond; including through the use of appropriate automated collection techniques or other forms of information technology, *e.g.* , permitting electronic submission of responses. This notice also lists the following information: *Title of Proposal:* Legal Instructions Concerning Applications for Full Insurance Benefits—Assignment of Multifamily Mortgage to the Secretary. *OMB Control Number, if applicable:* 2510-0006. *Description of the need for the information and proposed use:* Mortgagees of HUD-insured mortgages may receive mortgage insurance benefits upon assignment of mortgages to HUD. In connection with the assignment, legal documents ( *e.g.* , mortgage, mortgage note, security agreement, title insurance policiy) must be submitted to the Department. The instructions describe the documents to be submitted and the procedures for submission. *Agency form numbers, if applicable:* N/A. *Members of affected public:* Mortgagees when applying for insurance benefits from HUD. *Estimation of the total number of hours needed to prepare the information collection including number of respondents, frequency of response, and hours of response:* Number of respondents Burden hours Frequency of response Total burden hours 359 26 1 9,334 *Status of the proposed information collection:* Extension of a currently approved collection. Authority: The Paperwork Reduction Act of 1995, 44 U.S.C. Chapter 35, as amended. Dated: April 25, 2006. Camille E. Acevedo, Associate General Counsel Legislation and Regulations. [FR Doc. E6-6545 Filed 5-1-06; 8:45 am] BILLING CODE 4210-67-P DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT [Docket No. FR-4964-N-02] Annual Indexing of Basic Statutory Mortgage Limits for Multifamily Housing Programs AGENCY: Office of the Assistant Secretary for Housing—Federal Housing Commissioner, HUD. ACTION: Notice. SUMMARY: In accordance with section 206A of the National Housing Act, HUD has adjusted the basic statutory mortgage limits for multifamily housing programs for calendar year 2006. EFFECTIVE DATE: January 1, 2006. FOR FURTHER INFORMATION CONTACT: Joseph E. Malloy, Acting Director, Office of Multifamily Development, Department of Housing and Urban Development, 451 Seventh Street, SW, Washington, DC 20410-8000, telephone

(202)708-1142 (this is not a toll-free number). Hearing-or speech-impaired individuals may access this number through TTY by calling the toll-free Federal Information Relay Service at

(800)877-8339. SUPPLEMENTARY INFORMATION: The FHA Downpayment Simplification Act of 2002 (Pub. L. 107-326, approved December 4, 2002) amended the National Housing Act by adding a new section 206A (12 U.S.C. 1712a). Under section 206A, the following are affected:

(1)section 207(c)(3)(A) (12 U.S.C. 1713(c)(3)(A));

(2)section 213(b)(2)(A) (12 U.S.C. 1715e(b)(2)(A));

(3)section 220(d)(3)(B)(iii)(I) (12 U.S.C. 1715k(d)(3)(B)(iii)(I));

(4)section 221(d)(3)(ii)(I) (12 U.S.C. 1715l(d)(3)(ii)(I));

(5)section 221(d)(4)(ii)(I) (12 U.S.C. 1715l(d)(4)(ii)(I));

(6)section 231(c)(2)(A) (12 U.S.C. 1715v(c)(2)(A)); and

(7)section 234(e)(3)(A) (12 U.S.C. 1715y(e)(3)(A)). The dollar amounts in these sections, which are collectively referred to as the ‘Dollar Amounts,’ shall be adjusted annually (commencing in 2004) on the effective date of the Federal Reserve Board's adjustment of the $400 figure in the Home Ownership and Equity Protection Act of 1994 (HOEPA) (Pub.L. 103-325, approved September 23, 1994). The adjustment of the Dollar Amounts shall be calculated using the percentage change in the Consumer Price Index for All Urban Consumers (CPI-U) as applied by the Federal Reserve Board for purposes of the above-described HOEPA adjustment. HUD has been notified of the percentage change in the CPI-U used for the HOEPA adjustment and the effective date of the HOEPA adjustment. The percentage change in the CPI-U is 3.51 percent and the effective date of the HOEPA adjustment is January 1, 2006. The Dollar Amounts have been adjusted correspondingly and have an effective date of January 1, 2006. The adjusted Dollar Amounts for calendar year 2006 are shown below: Basic Statutory Mortgage Limits for Calendar Year 2006 Multifamily Loan Program • Section 207—Multifamily Housing. • Section 207 pursuant to section 223(f)—Purchase or refinance housing. • Section 220—Housing in urban renewal areas. Bedrooms Non- elevator Elevator 0 $41,154 47,486 1 45,585 53,183 2 54,449 65,213 3 67,112 81,675 4+ 75,977 92,349 • Section 213—Cooperatives. Bedrooms Non- elevator Elevator 0 $44,597 47,486 1 51,420 53,800 2 62,015 65,419 3 79,378 84,631 4+ 88,431 92,900 • Section 221(d)(3)—Moderate income housing. • Section 234—Condominium housing. Bedrooms Non- elevator Elevator 0 $45,507 47,890 1 52,470 54,897 2 63,279 66,755 3 80,998 86,358 4+ 90,235 94,795 • Section 221(d)(4)—Moderate income housing. Bedrooms Non- elevator Elevator 0 $40,955 44,239 1 46,488 50,714 2 56,192 61,667 3 70,531 79,776 4+ 79,923 87,571 Section 231—Housing for the Elderly. Bedrooms Non- elevator Elevator 0 $38,938 44,239 1 43,529 50,714 2 51,980 61,667 3 62,553 79,776 4+ 73,541 87,571 • Section 207—Manufactured Home Parks. Per Space—$18,895 Dated: April 19, 2006. Brian D. Montgomery, Assistant Secretary for Housing-Federal Housing Commissioner. [FR Doc. E6-6543 Filed 5-1-06; 8:45 am] BILLING CODE 4210-67-P DEPARTMENT OF THE INTERIOR Bureau of Land Management [ID-300-1020-PH] Notice of Public Meeting, Idaho Falls District Resource Advisory Council Meeting AGENCY: Bureau of Land Management, Interior. ACTION: Notice of public meeting. SUMMARY: In accordance with the Federal Land Policy and Management Act (FLPMA) and the Federal Advisory Committee Act of 1972 (FACA), the U.S. Department of the Interior, Bureau of Land Management

(BLM)Idaho Falls District Resource Advisory Council (RAC), will meet as indicated below. DATES: The meeting will be held June 6-7, 2006 starting at the Soda Springs City Council Chambers, 9 West 2nd South, Soda Springs, Idaho 83276. The meeting will start at 1 p.m. on June 6, with the public comment period as the first agenda item. The second day will conclude at or before 5 p.m. Following the first two hours of the meeting at the Soda Springs City Hall, the rest of the meeting will be conducted as a field tour. Meeting attendees outside of BLM staff and RAC members should provide their own transportation if they wish to participate. SUPPLEMENTARY INFORMATION: The 15-member Council advises the Secretary of the Interior, through the Bureau of Land Management, on a variety of planning and management issues associated with public land management in the BLM Idaho Falls District (IFD), which covers eastern Idaho. At this meeting, the Advisory Council will receive updates on current IFD and BLM Idaho issues. The field tour for the RAC will be to Blackfoot Reservoir Campground on June 6 and the Simplot Smoky Canyon Mine on June 7. All meetings are open to the public. The public may present written comments to the Council. Each formal Council meeting will also have time allocated for hearing public comments. Depending on the number of persons wishing to comment and time available, the time for individual oral comments may be limited. Individuals who plan to attend and need special assistance, such as sign language interpretation, tour transportation or other reasonable accommodations, should contact the BLM as provided below. FOR FURTHER INFORMATION CONTACT: David Howell, RAC Coordinator, Idaho Falls District, 1405 Hollipark Dr., Idaho Falls, ID 83401. Telephone

(208)524-7559. E-mail: *David_Howell@blm.gov* . Dated: April 26, 2006. David Howell, RAC Coordinator, Public Affairs Specialist. [FR Doc. E6-6585 Filed 5-1-06; 8:45 am] BILLING CODE 4310-GG-P DEPARTMENT OF THE INTERIOR National Park Service National Register of Historic Places; Notification of Pending Nominations and Related Actions Nominations for the following properties being considered for listing or related actions in the National Register were received by the National Park Service before April 22, 2006. Pursuant to § 60.13 of 36 CFR part 60 written comments concerning the significance of these properties under the National Register criteria for evaluation may be forwarded by United States Postal Service, to the National Register of Historic Places, National Park Service, 1849 C St. NW., 2280, Washington, DC 20240; by all other carriers, National Register of Historic Places, National Park Service, 1201 Eye St. NW., 8th floor, Washington DC 20005; or by fax, 202-371-6447. Written or faxed comments should be submitted by May 17, 2006. John W. Roberts, Acting Chief, National Register/National Historic Landmarks Program. Alabama Calhoun County Profile Cotton Mills Historic District, Alexandria St., A St., H St., and D St., Jacksonville, 06000436 Colbert County Muscle Shoals Sound Studio, 3614 Jackson Hwy., Sheffield, 06000437 Jefferson County Woodlawn Highlands Historic District, Bounded by 5th Ave. S, Crestwood Blvd., and 56th and 61st. Sts. S, Birmingham, 06000438 Montgomery County Winter Place, 454 S. Goldwaite St., Montgomery, 06000439 Alaska Southeast Fairbanks Borough-Census Area F.E. Company Dredge No. 4, 0.25 mi. Chicken Airport Rd., mi. 66.4 Taylor Hwy, Chicken, 06000435 Arizona Maricopa County Medlock Place Historic District, Roughly bounded by Missouri Ave., Camelback Rd., 7th Ave. and Central Ave. Phoenix, 06000434 Arkansas Clay County Piggott National Guard Armory, 775 E. Main St., Piggott, 06000440 Desha County McGehee National Guard Armory, 1610 S. First St., McGehee, 06000441 Florida Hillsborough County Roosevelt Elementary School, 3205 S. Ferdinand Ave., Tampa, 06000443 Martin County Seminole Inn, 15885 SE Warfield Blvd., Indiantown, 06000442 Georgia Cobb County Moore, Tarleton, House, 4784 Northside Dr., Acworth, 06000453 Illinois Cook County Krause Music Store, 4611 N. Lincoln Ave., Chicago, 06000452 Union Park Congregational Church and Carpenter Chapel, 1613 W. Washington Blvd., Chicago, 06000446 Henry County Kewanee Public Library, (Illinois Carnegie Libraries MPS) 102 S Tremont, Kewanee, 06000447 Kankakee County Downtown Momence Historic District, Roughly Washington St., from N. Locust to Pine and Dixie Hwy., from 2nd to River, Momence, 06000449 Durham—Perry Farmstead, 459 N. Kennedy Dr., Bourbonnais, 06000445 Sangamon County Jennings Ford Automobile Dealership, 431 S. Fourth St., Springfield, 06000450 Will County McGovney—Yunker Farmstead, 10824 LaPorte Rd., Mokena, 06000448 Iowa Woodbury County Swedish Evangelical Lutheran Augustana Church, 600 Court St., Sioux City, 06000444 Maryland Anne Arundel County Linthicum Heights Historic District, Roughly bounded by Camp Meade Rd., Homewood Rd., Twin Oaks Rd. Locust Grove Rd. and Forest View Rd., Linthicum, 06000451 Minnesota Fillmore County Milwaukee Elevator, (Grain Elevator Design in Minnesota MPS), Fillmore Street and Root River State Trail, Preston, 06000454 St. Louis County Duluth Commercial Historic District, Superior and 1st bet. 4th Ave. W and 4th Ave. E, Duluth, 06000455 South Dakota Clay County Bluff View Cemetery Chapel, 0.2 mi. S of jct. of Crawford Rd. and Pinehurst Dr., Vermillion, 06000458 Fall River County Bartlett—Myers Building, 506 1/2 2nd Ave., Edgemont, 06000457 Hughes County Hilger Block, 361 S. Pierre, Pierre, 06000456 Miner County Coughlin House, 260 W. Main St., Carthage, 06000460 Minnehaha County Tuthill, John W., Lumber Company, 311 E. 8th St., Sioux Falls, 06000459 Union County Swanson House, 30572 483rd Ave., Alcester, 06000461 A request for REMOVAL has been made for the following resource: South Dakota Lawrence County Sunderland, James, House 711 Canyon, Spearfish, 90001648 [FR Doc. 06-4126 Filed 5-1-06; 8:45 am]

Connectionstraces to 8

Traces to 8 documents

U.S. Code